Dr. Burke Discusses the STARGLO and AQUILA Trials | Chief Insights in Oncology

31 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In this month's Chief Insights, John M. Burke, MD, hematologist-oncologist at Rocky Mountain Cancer Centers and editor-in-chief of Targeted Therapies in Oncology, discusses his column from the July issue regarding the FDA's Oncologic Drug Advisory Committee (ODAC) meetings held in May of this year on glofitamab in DLBCL and the STARGLO trial, as well as daratumumab in high-risk smoldering myeloma and the AQUILA trial.

Read Dr. Burke's column: https://www.targetedonc.com/view/fda-s-oncologic-drugs-advisory-committee-casts-interesting-votes

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Categoria
Oncology
Commenta per primo questo video.

Prossimo